New research on a mutation in TREM2 validates GliaCure’s approach to Alzheimer’s disease.
The New England Journal of Medicine recently included papers detailing research from two groups pointing to a mutation in the gene TREM2 as a risk factor for Alzheimer’s disease. This mutation appears to lead to inflammation of the brain and decreased clearing of amyloid beta plaques. In discussing these papers Harald Neumann and Mark J. Daly suggest that:
“… the degeneration of neurons in … TREM2-associated Alzheimer’s disease is driven by a chronic inflammatory process with dysfunction in the microglial phagocytosis or inflammatory pathway.”
As GliaCure’s approach to drug development in Alzheimer’s is focused on a microglial target to enhance microglial phagocytosis and to clear amyloid beta these exciting new findings suggest that the company is on the right track.
The full editorial from the NEJM can be found here.
This research was also reported in The New York Times. The news report can be found here.